Clinical Trials Browser

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05047250 2026-03-11

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06066138 2026-03-11

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

30 enrolled

DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 1 FDA

Thoracic

Small Cell Lung Carcinoma

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

136 enrolled

Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT04302025 2026-03-06

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

99 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

Thoracic

Lung Neoplasms

NCT06646276 2026-03-04

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

530 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting

184 enrolled

Thoracic

Bites and Stings, Lung Neoplasms

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07284121 2026-02-27

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Recruiting

700 enrolled

GastrointestinalThoracic

Carcinoma, Hepatocellular, Lung Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Completed

131 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT07227597 2026-02-20

MK-6070-003

Phase 1/2 Recruiting

170 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage